Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMRT plus induction versus concurrent docetaxel/cisplatin-based chemotherapy for locally advanced nasopharyngeal carcinoma
ChiCTR-TRC-14004341Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Shantou University Medical College
- Start
- Mar 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel and cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Affiliated Cancer Hospital of Shantou University Medical College. Primary endpoints: Short-term effect and 2-year progression-free survival. Started Mar 2014; status: recruiting.
02
Drugs
docetaxelcisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR-TRC-14004341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14004341.